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Abstract
Background: The majority of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor
(EGFR) mutation eventually develop resistance to EGFR tyrosine kinase inhibitors (TKIs). Minimal information exists
regarding genetic alterations in rebiopsy samples from Asian NSCLC patients who develop acquired resistance to
EGFR-TKIs.
Methods: We retrospectively reviewed the medical records of patients with NSCLC harboring EGFR mutations who
had undergone rebiopsies after developing acquired resistance to EGFR-TKIs. We analyzed 27 practicable samples
using a tumor genotyping panel to assess 23 hot-spot sites of genetic alterations in nine genes (EGFR, KRAS, BRAF,
PIK3CA, NRAS, MEK1, AKT1, PTEN, and HER2), gene copy number of EGFR, MET, PIK3CA, FGFR1, and FGFR2, and ALK,
ROS1, and RET fusions. Additionally, 34 samples were analyzed by commercially available EGFR mutation tests.
Results: Sixty-one patients underwent rebiopsy. Twenty-seven samples were analyzed using our tumor genotyping
panel, and 34 samples were analyzed for EGFR mutations only by commercial clinical laboratories. Twenty-one
patients (34%) had EGFR T790M mutation. Using our tumor genotyping panel, MET gene copy number gain was
observed in two of 27 (7%) samples. Twenty patients received continuous treatment with EGFR-TKIs even after
disease progression, and 11 of these patients had T790M mutation in rebiopsy samples. In contrast, only 10 of 41
patients who finished EGFR-TKI treatment at disease progression had T790M mutation. The frequency of T790M
mutation in patients who received continuous treatment with EGFR-TKIs after disease progression was significantly
higher than that in patients who finished EGFR-TKI treatment at disease progression (55% versus 24%, p = 0.018).
Conclusions: The frequency of T790M mutation in this study was lower than that in previous reports examining
western patients. These results suggest that continuous treatment with EGFR-TKI after disease progression may
enhance the frequency of EGFR T790M mutation in rebiopsy samples.
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Background
Lung cancer is the most common cause of cancer-related
deaths, and non-small cell lung cancer (NSCLC) accounts
for approximately 85% of all lung cancers [1, 2]. Over
70% of patients with NSCLC have advanced disease at
the time of diagnosis, and prognosis is generally poor [3].
Recently, molecular targeted therapies have been devel-
oped and have provided a remarkable benefit to NSCLC
patients with specific genetic alterations. In particular,
NSCLC with mutation in the epidermal growth factor
receptor (EGFR) gene are sensitive to EGFR blockade with
specific tyrosine kinase inhibitors (TKIs). EGFR-TKIs are
efficacious in patients with NSCLC harboring EGFR mu-
tations as demonstrated in prospective clinical trials [4–8].
However, in spite of this efficacy almost all patients with
EGFR-mutant NSCLC develop resistance to EGFR-TKIs.
Various mechanisms of resistance to EGFR-TKIs have
been identified, and understanding these is critical for
development of effective treatment strategies for EGFR-
TKI-resistant NSCLC. The major mechanism of ac-
quired resistance reported is secondary T790M mutation
on exon 20 on the EGFR gene [9–12]. This secondary
mutation enhances ATP-binding affinity of EGFR-mu-
tated cells. Since EGFR-TKIs are competitive ATP-
inhibitors, their efficacy is decreased in the face of the
T790M mutation [13]. Additional mechanisms include
amplification of the MET gene [11, 12, 14], PIK3CA mu-
tation [11, 15], BRAF mutation [16], epithelial-to-
mesenchymal transition (EMT) [11], and small cell lung
cancer (SCLC) transformation [11, 12].
Several studies have examined the mechanisms and
frequency of EGFR-TKI resistance, though minimal data
regarding Japanese patients exist. Furthermore, the clinical
factors that influence the frequency of acquired resistance
mutations, especially T790M, remain unclear. This study
aimed to analyze the causes of acquired resistance to
EGFR-TKIs in Japanese patients with NSCLC, and to




We reviewed the medical records of consecutive patients
with NSCLC harboring EGFR mutations who had under-
gone rebiopsies based on physician’s decision in the cases
of acquired resistance to EGFR-TKI. Most rebiopsy sam-
ples were obtained from sites assessed as disease progres-
sion by imaging. Patients were treated at the Shizuoka
Cancer Center between September 2002 and August
2014. Acquired resistance was defined according to
Jackman’s criteria [17]. The criteria defined acquired
resistance as progression while receiving EGFR-TKI, after
initial response or durable stable disease (>6 months). The
written informed consent regarding EGFR mutational
analysis was obtained from most patients, and verbal in-
formed was from some patients since EGFR mutational
analysis was performed under the Japanese insurance
system. Additionally, some patients were enrolled in the
Shizuoka Lung Cancer Mutation Study [18], and these
samples were analyzed using our tumor genotyping panel.
This study protocol was approved by the Institutional
Review Board of Shizuoka Cancer Center under number
27–J102–27–1–3.
Mutational profiling
A tumor genotyping panel was designed to assess 23
hotspot sites of genetic alterations in 9 genes (EGFR,
KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN, and
HER2), gene copy number of EGFR, MET, PIK3CA,
FGFR1, and FGFR2, and ALK, ROS1, and RET fusions
using pyrosequencing plus capillary electrophoresis,
quantitative polymerase chain reaction (PCR), and
reverse transcription PCR, respectively (Table 1). We
analyzed samples from patients enrolled in the Shizuoka
Lung Cancer Mutation Study, using this tumor genotyp-
ing panel. The other samples were analyzed for EGFR
mutations using the Scorpion ARMS or Cycleave
methods by a commercial clinical laboratory (SRL Inc.,
Tokyo, Japan) (see Additional file 1).
Evaluation of efficacy
Responsiveness to EGFR-TKI treatment was evaluated
according to the Response Evaluation Criteria in Solid
Tumors version 1.1 [19]. Progression-free survival (PFS)
was defined as the period between the start of EGFR-
TKI treatment and progressive disease or death from
any cause. Overall survival (OS) was defined as the
period between the start of EGFR-TKI treatment and the
date of death from any cause.
Statistical analysis
All categorical variables were analyzed by the chi-square
test or Fisher’s exact test, as appropriate. Continuous
variables were analyzed using the Mann-Whitney test.
Logistic regression analyses were used to adjust for
potential confounding factors. All p values < 0.05 were
considered statistically significant. All analyses were per-
formed using JMP 10 for Windows statistical software
(SAS Institute Japan Inc., Tokyo, Japan).
Results
Patient characteristics
Sixty-one patients with NSCLC harboring EGFR muta-
tions, and who had undergone rebiopsy after acquired re-
sistance to EGFR-TKI at the Shizuoka Cancer Center were
included in this study. Patient characteristics are shown in
Table 2. The median age (range) was 64 (39–84) years,
and most patients were female (72%) and never-smokers.
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All patients had been diagnosed with adenocarcinoma of
the lung with activating EGFR mutations at initial diagno-
sis. The types of EGFR mutations before the initial EGFR-
TKI treatment were exon 19 deletion in 37 patients
(61%), exon 21 L858R in 19 patients (31%), and other/
double EGFR mutations in five patients (8%). Thirty-nine
patients (64%) were treated with EGFR-TKI as first-line
therapy. Twenty-two patients (36%) received EGFR-TKI
as second or subsequent-line therapy. Forty-nine patients
(80%) were treated with gefitinib, seven patients (12%)
with erlotinib, and five patients (8%) with other EGFR-
TKIs including afatinib. All patients received EGFR-TKI
monotherapy. Twenty patients received continuous treat-
ment with EGFR-TKI more than 30 days after disease pro-
gression, and 41 patients finished EGFR-TKI treatment
within 29 days after diagnosis of disease progression.
Rebiopsy
Table 3 depicts characteristics of rebiopsy sites, speci-
mens, and procedures in patients who had undergone
rebiopsy after developing acquired resistance to EGFR-
TKIs. Because of their easy accessibility and practical
necessity, serous effusions such as pleural effusion and
cerebrospinal fluid account for more than half of the
specimens. Pulmonary lesions were also rebiopsied, with
the most common procedure being transbronchial
biopsy. Biopsy samples from lymph nodes or other sites
were obtained using computed tomography-guided or
sonography-guided needle biopsy. All rebiopsies were
performed after stopping EGFR-TKI treatment.
Resistance mechanisms
A total of 61 rebiopsy samples were analyzed for EGFR
mutations. Twenty-seven rebiopsy samples were ana-
lyzed using our tumor genotyping panel, and 34 samples
were examined for EGFR mutations by commercial clin-
ical laboratories. All of 61 patients had EGFR activating
mutations before EGFR-TKI treatment, and 55 patients
(90.2%) still had same EGFR mutations in rebiopsy sam-
ples. T790M mutation was identified in 21 of 61 samples
(34.4%; Fig. 1). No samples had small cell histologic
transformation. In samples analyzed using our tumor
genotyping panel, MET gene copy number gain was seen
in two of 27 samples (7%). Additionally, we detected
Table 1 Multiplexed tumor genotyping panel
Gene name Position AA mutant Nucleotide mutant
EGFR G719 G719 2155G > T/A
G719A 2156G > C
exon 19 Deletion
T790 T790M 2369C > T
exon20 Insertion
L858 L858R 2573 T > G
L861 L861Q 2582 T > A
KRAS G12 G12C/S/R 34G > T/A/C
G12V/A/D 35G > T/C/A
G13 G13C/S/R 37G > T/A/C
G13D/A 38G > A/C
Q61 Q61K 181C > A
Q61R/L 182A > G/T
Q61H 183A > T/C
BRAF G466 G466V 1397G > T
G469 G469A 1406G > C
L597 L597V 1789C > G
V600 V600E 1799 T > A
PIK3CA E542 E542K 1624G > A
E545 E545K/Q 1633G > A/C
H1047 H1047R 3140A > G
NRAS Q61 Q61K 181C > A
Q61L/R 182A > T/G
MEK1 (MAP2K1) Q56 Q56P 167A > C
K57 K57N 171G > T
D67 D67N 199G > A
AKT1 E17 E17K 49G > A
PTEN R233 R233 697C > T
HER2 exon20 Insertion







Smoking history, n (%)
Never 44 (72%)
Former/Current 17 (28%)
ECOG performance status, n (%)
0–1 52 (85%)
2–4 9 (15%)
Pretreatment EGFR status, n (%)
Exon19 deletion 37 (61%)
Exon21 L858R 19 (31%)
Other 5 (8%)
EGFR TKI, n (%)
Gefitinib 49 (80%)
Erlotinib 7 (12%)
2nd generation 5 (8%)
Abbreviations: ECOG eastern cooperative oncology group, EGFR epidermal
growth factor receptor, TKI tyrosine kinase inhibitor
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PIK3CA mutation (E542K), BRAF mutation (G466V),
and KRAS mutation (G12D), in one sample each in 27
samples (4%) (Fig. 2). Six of 61 rebiopsy samples (9.8%)
did not possess EGFR mutation, despite having EGFR
activating mutations at the initial analysis. KRAS muta-
tion was detected in 1 of these samples.
T790M prevalence
Correlations between patient characteristics and T790M
prevalence were evaluated (Table 4). Eleven of 20
patients who received continuous treatment with EGFR-
TKI after disease progression had T790M mutation in
the rebiopsy sample. However, only 10 of 41 patients
who had finished EGFR-TKI treatment at the time of
disease progression had T790M mutation (Fig. 3). The
frequency of T790M mutation in patients who received
continued treatment with EGFR-TKI after disease pro-
gression was significantly higher than in patients who
finished EGFR-TKI at diagnosis of disease progression
(55% versus 24%, p = 0.018). Multivariate analysis also
demonstrated that continuous treatment with EGFR-TKI
after disease progression was significantly correlated
with T790M mutation (Table 4). Other characteristics,
including PFS with EGFR-TKI, rebiopsy site, and
rebiopsy sample, had no statistical association with the
prevalence of T790M.
Discussion
Previous reports from examining patients in western
countries have reported EGFR T790M mutation in 49–
69% patients with NSCLC harboring EGFR mutations
who had undergone rebiopsy after developing acquired
resistance to EGFR-TKIs [11, 12, 20]. In contrast, our
study identified T790M mutation in only 21 of 61
rebiopsy samples (34.4%). This finding is similar to that
of the one other Japanese study we are aware of [21].
Therefore, T790M prevalence in Japanese and Western
patients may be different. In our study, only 30% of pa-
tients received continuous treatment with EGFR-TKI
after disease progression. Shimilarly, few such patients
were included in the study from Hata et al. [21]. However,
88–91% of patients in previous studies from western
countries received continuous treatment with EGFR-TKI
after disease progression [12, 20]. Additionally, the
frequency of T790M mutation in patients who received
continuous treatment with EGFR-TKI after disease pro-
gression was significantly higher than that in patients who
had finished EGFR-TKI treatment by diagnosis of disease
progression in our study. Furthermore, the preclinical
report showed that continuous exposure to EGFR-TKIs
induced T790M mutation in a NSCLC cell line with an
EGFR-sensitive mutation [22]. These data suggest that
continued treatment with EGFR-TKIs after disease pro-
gression may promote T790M mutation. While differ-
ences in ethnicity and analysis methods may underlie
these inconsistencies, the potential for EGFR-TKIs to
promote T790M mutation should not be overlooked.
Table 3 Procedures and specimens of rebiopsy samples obtained
from NSCLC patients with EGFR mutations













Fig. 1 Frequency of T790M mutation in rebiopsy samples (n = 61)
Fig. 2 Multimutational profiling in rebiopsy samples analyzed using
our tumor genotyping panel (n = 27). CNG: Copy number gain
Ko et al. BMC Cancer  (2016) 16:864 Page 4 of 8
The frequencies of MET gene copy number gain and
PIK3CA mutation in our study were similar to those
previously reported in studies from western countries
[11, 12]. Furthermore, BRAF mutation is associated with
acquired resistance to EGFR-TKIs [16]. We also detected
KRAS mutation in one rebiopsy sample. KRAS and
EGFR mutations have previously been considered mutu-
ally exclusive [23]. However, Kuiper et al. recently re-
ported KRAS mutation in one rebiopsy sample following
development of acquired resistance to EGFR-TKIs [24].
Table 4 Multivariate and univariate analyses of patient characteristics and T790M prevalence in patients with NSCLC harboring EGFR
mutations, who had undergone rebiopsy after acquired resistance to EGFR-TKI (n = 61)
Patient characteristics Number T790M (%) P (Univariate) P (Multivariate)
Age 0.9292
≥75 12 4 (33%)
<74 49 17 (35%)
Sex 0.4904
Female 44 14 (32%)
Male 17 7 (41%)
Smoking history 0.4904
Never 44 14 (32%)
Former/current 17 7 (41%)
EGFR mutation status 0.1038
Exon19 deletion 37 9 (24%)
Exon21 L858R 19 9 (47%)
Other 5 3 (60%)
Rebiopsy site 0.5813 0.9133
Central nervous system 11 3 (27%)
Other 50 18 (36%)
Rebiopsy sample 0.2017 0.5016
Tissue 28 12 (43%)
Fluid 33 9 (27%)
EGFR TKI 0.1208
Gefitinib 49 17 (35%)
Erlotinib 7 4 (57%)
2nd generation 5 0 (0%)
Line of EGFR-TKI 0.4235
1st 39 12 (31%)
2nd or later 22 9 (41%)
History of platinum doublet until rebiopsy 0.7021
Yes 34 11 (32%)
No 27 10 (37%)
PFS with EGFR-TKI 0.4823
≥10 months 34 13 (38%)
<10 months 27 8 (30%)
Interval between RECIST PD and rebiopsy 0.2766
≥4 months 29 12 (41%)
<4 months 32 9 (28%)
Period of continuation of TKI beyond PD 0.0182 0.0417
≥30 days 20 11 (55%)
<30 days 41 10 (24%)
Abbreviations: EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, PFS progression free survival, PD progressive disease
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Furthermore, Li et al. have identified double mutation of
EGFR and KRAS in pretreatment assessment of NSCLC
patients [25]. These data suggest that KRAS mutation
may promote acquired resistance to EGFR-TKIs through
drug selective pressure. However, more data are required
to confirm this hypothesis.
The availability of continuous treatment with EGFR-
TKIs after disease progression is still controversial. In
IMPRESS trial, continuation of gefitinib treatment
after disease progression on gefitinib monotherapy did
not prolong progression-free survival and overall sur-
vival in patients who received platinum-based doublet
chemotherapy as subsequent line of treatment [26].
However, it is unclear that the efficacy of continuous
using EGFR-TKIs without platinum doublets [27, 28].
Recently, we had been able to use third generation
EGFR-TKIs that have great efficacy for NSCLC with
EGFR T790M mutation in clinical practice. If there
are relationship between the continuous treatment
with EGFR-TKIs after disease progression and the
frequency of T790M, the continuous therapy can be
more important choice.
Our study had several limitations. First, we retrospect-
ively collected the data from a single institution, and our
sample size was small. This small sample size results from
the difficulty surrounding rebiopsy in clinical practice.
Second, we analyzed only 27 rebiopsy samples (44.3%)
using our tumor genotyping panel. Therefore, further
multi-institutional studies are warranted to verify our
results.
Conclusions
The frequency of T790M mutation in rebiopsy samples in
our study was lower than that reported in previous reports
studies of western patients. The frequency of T790M mu-
tation in patients who received continuous treatment with
EGFR-TKIs after disease progression was significantly
higher than that in patients who stopped EGFR-TKI treat-
ment at diagnosis of disease progression. Continuous
treatment with EGFR-TKI following disease progression
may therefore influence the frequency of EGFR T790M
mutations in rebiopsy samples.
Additional file
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